INTRODUCTION
The concept of immunosuppression was initially proposed by Gershon et al in the early 1970s when they demonstrated that tolerance to sheep red blood cells, induced upon the injection of high doses of the tolerogen, was not only a T-cell-dependent phenomenon but that it could be transferred to naïve hosts upon the infusion of T cells from the tolerant mice (1) . The term "infectious tolerance" was coined to describe the phenomenon (2) and the term "suppressor cells" was coined to describe a subset with suppressive activity (1) . It has been considered to be one of the most important discoveries in immunology in this century made by Gershon and his student Kondo. Ha et al obtained more direct evidence for the presence and migration of suppressor cells. Thymocytes collected 24 hr after a large intraperitoneal dose of bovine gamma globulin (BGG), washed, and transferred to normal hosts produced a specific deficit in the recipients of both humoral and cell-mediated response to BGG. This effect was mediated by cells of low to intermediated density and was inhibited by treating these cells before transfer with antimycin A or cycloheximide, but not mitomycin C or actionomycin D. Thus the transferred tolerance depended on an active process involving living specific regulatory cells and protein synthesis. And the term "thymic suppressor cells" was named to describe thymocytes with suppressor activity (3) (4) (5) . Evidence was accumulating to support the concept of thymic regulatory or suppressor function in a number of other experimental systems (6) (7) (8) (9) (10) .
However, since the hypothetical soluble suppressor factor could not be identified on a molecular level and since appropriate cellular markers were lacking at that time, the suppressor T cells concept and even the existence of suppressor T cells was drawn into question for a considerable time (11, 12) . Despite these adverse circumstances, numerous experiments were performed that gave clear indication that such cells may indeed exist (6, 9, 10, (13) (14) (15) (16) (17) (18) (19) (20) (21) . The whole concept of suppression and suppressor T cells was revived by a few papers published in the mid-1990s. In 1995, Sakaguchi et al were first discovered CD4+CD25+ regulatory T cells (22) . They demonstrated that transfer of lymphoid-cell populations from which CD4+ T cells expressing the α-chain of the IL-2 receptor (IL-2Rα; also known as CD25) into athymic BALB/c nude mice had been removed caused spontaneous development of various T cell-mediated autoimmune diseases. Furthermore, reconstitution with CD4+CD25+ T cells pre- vented the development of autoimmunity. CD4+CD25+ T cells were named regulatory T cells (Treg cells) and since then have been intensively characterized by many groups (23) (24) (25) (26) (27) (28) . Now the terms "suppressor T cells" and "regulatory T cells" are sometime used interchangeably, but the term "Treg cells" is preferred by most researchers. It has been now been well documented in a variety of models that CD4+CD25+ Treg cells play indispensable roles in the maintenance of natural tolerance, in averting autoimmune responses, as well as in controlling inflammatory reactions. Anyhow, this great discovery challenged traditional theories about clonal deletion being the only mechanism of self-tolerance and provided convincing evidence that self-antigen-reactive T cells that cause autoimmune disease can be controlled through active suppression by natural Treg cells.
BIOLOGY OF REGULATORY T CELLS
CD4+CD25+ Treg cells, which constitute 5∼10% of peripheral T cells in mice, are continuously produced in thymus as a functionally mature T-cell population that includes cells with immunosuppressive activity in vitro and in vivo. However, CD25 is not a definite definitive marker of natural Treg cells, namely CD25 is an activation marker for T cells and is therefore also expressed by effector Th1 and Th2 cells (28, 29 (29, 43) . Putative surface molecules for regulatory T cells include cell-surface expression of lymphoid homing receptors CD38, CD621, CD103 (integrin αEβ7), cytotoxic T-lymphocytes antigen-4(CTLA-4), glucocorticoid induced tumor necrosis factor receptor related protein (GITR), the chemokine receptors CCR4 and CCR8, low levels of cell-surface CD45RB expression, lymphocyte activation gene-3 (LAG-3), intracellulaur expression of the transcriptional repressor forkhead box P3 (FOXP3) (44) . FOXP3 seems to be the most promising key marker of natural regulatory T cells and was reported to be essential for the development and functional activity of CD25+ Treg cells (36, 37) . In addition, Foxp3 gene transfer was shown to convert naïve CD4+CD25-T cells into a functional regulatory population, demonstrating the pivotal role of Foxp3 in Treg cell biology (23, 36, 37) . Importantly, although the identification of FOXP3 as a key regulator of Treg-cell development and function has facilitated their identification in mice, many activated (non-regulatory) human T cells also express FOXP3, precluding it as a useful marker for human Treg cells. Namely, expression of FOXP3 mRNA is not confined to CD4+CD25+ T regulatory cells in humans (29, 43) . Consequently, the search for Treg-cell specific cell-surface markers, particularly in humans, has continued in earnest with a growing number of candidates proposed (45) (46) (47) showed that Treg cells and Nrp1+ Treg cells levels dropped in the tumor-draining lymph nodes of patients with cervical cancer following preoperative chemoradiotherapy in a direct relationship with the reduction of tumor mass, suggesting that suppressor cell elimination facilitated the generation of T cells mediating the destruction of the neoplastic cells left behind after cytotoxic therapy. It is also interesting that Nrp1 is a receptor for transforming growth factor β-1 and promotes regulatory T cell activity (51) . Despite the mechanistic complexity, Treg cells are potent suppressors and they play a pivotal role in the control of autoimmunity, allergy, and transplantation tolerance (13, 16, 52) . This review attempts to outline current understanding of immunobiology of Treg cells and provides an update on the role of Treg cells in cell-based intervention autoimmune diseases. In addition, I discuss new findings in relation to possible targeting of Treg cell for immune modulation of the diseases and focuses on the potential therapeutic application of Treg cells in this exciting field. In this Review, unless otherwise stated, I primarily focus on thymus-derived, naturally occurring D4+CD25+Foxp3+/FOXP3+ T cells.
REGULATORY T CELL THERAPY FOR AUTOIMMUNE DISEASES
It is not surprising that Treg cells play an important role in the control of autoimmunity. This role is exemplified best by experiments involving reconstitution of immunodeficient nude mice with CD4+ T cells that were depleted of CD25+ cells. CD4+ CD25-T subset reconstituted nude mice develop various organ-specific autoimmune diseases, such as gastritis, oophoritis. orchitis and thyroiditis as shown in Fig. 2  (22,53-55) .
Infusion of the CD4+CD25+ subset in nude mice prevents the onset of these diseases (Fig. 3) . The protective value of CD4+CD25+ cells against organ-specific autoimmunity has also been shown in several other models of autoimmunity (53 (132, 133) .
Rheumatic arthritis (RA)
Accumulating evidence suggests that RA is a T-cell-mediated autoimmune disease and Treg cell defects in RA (126, 134) . The role of CD4+CD25+ T cells in pathogenesis and regulation of arthritis has been best studied in a mouse model of RA, collagen-induced arthritis (CIA). Depletion of Treg cells with anti-CD25 antibody before the onset of arthritis has been shown to result in increased cellular and humoral immune responses and increased arthritis severity (58) and adoptive transfer of CD4+CD25+ T cells was shown to result in decreased severity of CIA (72) . It is interesting that the administration of the vasoactive intestinal peptide (VIP), an immunosuppressive antiarthritic neuropeptide, to arthritic mice resulted in the expansion of CD4+CD25+ Foxp3+ Treg cells in the periphery and joints, which inhibited delayed type hypersensitivity and autoreactive T cell activation and expansion, and that the VIP-generated CD4+CD25+ Treg cell transfer suppressed and significantly ameliorated the progression of CIA, indicating that the generation of highly efficient Treg cells by VIP ex vivo could be used as an attractive therapeutic tool (135) (136) (137) (138) . There is a large body of data in the literature demonstrating that RA patients have defective CD4+CD25+ Treg cells and increased osteoclastogenesis. Recently, it has been reported that activated CD4+CD25+ Treg cells improve clinical symptoms of CIA, regulate cytokine production and inhibit osteoclastogenesis in vitro and in vivo (142) . Moreover, in several human studies, when examined in conventional in vitro assay, synovial CD4+CD25bright T cells in the patients with chronic rheumatic disease are able to suppress the proliferation of autologous CD4+CD25-(responder) T cells of synovial and peripheral origin (66,67). Synovial CD4+CD25+ T cells display an even increased suppressive capacity com-pared with blood CD4+CD25+ T cells in RA and in juvenile idiopathic arthritis (64). In CIA, depletion of CD4+CD25+ T cells accelerates the onset of severe disease, and transfer of syngeneic CD4+CD25+ T cells into Treg cell-depleted mice reverses the increased severity (58,72). One study showed that in arthritic joints, synovial fluid of patients with different rheumatic diseases such as undifferentiated arthritides, systemic rheumatic diseases and reactive arthritis, 95% of the patients had a higher frequency of CD25 bright CD4+ T cells in synovial fluid as compared with peripheral blood (69). Thus, local expansion in the CD4+CD25+ Treg cell population in the rheumatoid synovium might reflect a mechanism for resolving the inflammatory immune response. And CD4+CD25+ Treg cells in the inflamed rheumatoid synovium might be important for a down-regulation of the inflammation, thereby delaying further tissue damage and impeding erosive inflammation. Furthermore, interestingly, Behrens et al have shown, in human RA, the efficacy of autologuous Treg cells in reducing inflammatory activity of synovial tissue cell cultures ex vivo, while in the synovium Foxp3+ Treg cells of patients with RA are reduced compared with peripheral blood and synovial fluid, suggesting that this local imbalance of Th1 and Treg cells may be responsible for repeated rheumatic flares and thus will be of interest as a target for treatments (68).
Almost all current therapeutic concepts in autoimmune diseases are based on the systemic suppression of immune functions and are not curative. It is evident, however, that only the elimination of the cells secreting inflammatory mediators, rather than in the blockade of secreted molecules, will offer real specific therapeutic advantages in the future. Thus, direct and specific cell therapy of RA will become a true alternative to conventional therapies (143) . Indeed, emerging treatment paradigms such as autoantigenic peptides and cellular therapies are providing hope for a future in which immunopathology can be specifically and vigorously curtailed.
Autoimmune diabetes
Recent studies have provided convincing evidence that insulin-dependent diabetes mellitus (IDDM) or type 1 diabetes (T1D) is caused by an autoimmune destruction of pancreatic β cells, and inbred nonobese diabetic (NOD) mice develop spontaneous autoimmune diabetes that resembles human T1D in many respects (75, (79) (80) (81) 83) . It has been well established that diabetic process in NOD mice are regulated by a balance between diabetogenic T cells and regulatory T cells (83, 89) , and that a progressive defect in Treg cell function is, in part, responsible for T1D in Nod mice (76, 79, 81) . It has been reported that CD4+CD25+ Treg cells inhibit diabetes development and protection against spontaneous disease can be achieved during the preinsulitis and established insultitis phase of T1D by adoptive transfer of islet-specific Treg cells (75, 76, 78, 79, 82, 84) . The adaptive/polyclonal regulatory cells, which can be readily generated from normal CD4 populations can reverse T1D shortly after onset and become established as oligonal memory cells that persist indefinitely (＞1 year) as functionally stable Foxp3+, CD25-memory cells that transfer protection against T1D (75) . However, recently, it was reported that small number of pancreatic islet antigen-specific Treg cells were much more effective than polyclonal Treg cells in blocking and reversing diabetes in NOD mice and that islet peptide mimic-specific Treg cells can be expanded and used to prevent autoimmune diabetes in Treg cell-deficient NOD mice (79) . These results provided a direct demonstration of the presence of autoantigen-specific Treg cells in the natural setting that can be applied as therapeutics for organ-specific autoimmunity. Currently, Tritt et al have shown that CD4+Foxp3+nTreg cells also regulate later events of diabetogenesis by preferentially localizing in the pancreatic environment where they suppress the accumulation and function of effector T cell and that nTreg cell functional potency and intra-pancreatic proliferative potential declines with age, in turn augmenting diabetogenic responses and disease susceptibility (76) .
Interestingly, in human study, Tittanen et al investigated the peripheral blood mononuclear cells (PBMCs) from children with T1D and analyzed the effect of insulin treatment on Treg cells in children with T1D, and PBMCs were stimulated for 72 hr with bovine/human insulin. They found that the expression of Foxp3, CTLA-4 and ICOS mRNA in PBMCs stimulated with bovine or human insulin is higher in patients on insulin treatment than in patients studied before starting insulin treatment and the insulin-induced Foxp3 protein expression in CD4+CD25 high cells is detectable in flow cytometry, indicating that treatment with human insulin activates insulin-specific regulatory T cells in children with newly diagnosed T1D (80) . Coxsackievirus B4 (CB4) infections have long been associated with the induction of T1D. Currently, Richer et al reported that Treg cells induced after CB4 infection in the presence of TGF-beta prevented T1D. Furthermore, they reported that the presence of these viral induced Treg cells correlated with protection from T1D without altering the antiviral response. These experimental results described above have important implications not only for the basic understanding of Treg cell biology, but may also lead to an effective clinical therapy in autoimmune diabetes. (87) . Animal studies exploring the therapeutic effect of these cells raise the exciting possibility that strategies targeting these cell types may be effective in treating and preventing kidney disease in human. Wolf (88, 89) . These data indicate that Treg cells are able to use multiple mechanisms to suppress immune responses. Therefore, cellular therapy using Treg cells to reconstitute or strengthen regulatory function is an attractive option for many immune-mediated diseases. Importantly, gene therapy directed at the kidney has been difficult because of the problems of delivery of vector to the kidney. However, these results reported by Wang et al suggest that gene therapy by transduction of immune cells may overcome this barrier to treatment (89) . Accordingly, while it is an exciting prospect that regulatory cell could be used to dampen or even prevent renal disease, greater understanding of this therapeutic strategy, the disease being treated, and vigorously designed clinical trials are required before these therapies can be applied generally to human with renal disease.
Chronic kidney disease
Glomerulonephritis, the commonest cause of chronic kidney disease (CKD) and end-stage renal disease (ESRD), is thought of as immune mediated, while other forms of renal injury are often described as nonimmune. Recent data have shown that Treg cells are potent modulators of tissue injury and repair in renal diseases
Experimental autoimmune encyphalomyelitis (EAE), Multiple sclerosis (MS) and Parkinson's disease
EAE is an inflammatory, autoimmune demyelinating disease of the central nervous system (CNS) and a mouse model of human multiple sclerosis (144) . MS is a chronic inflammatory disease characterized by lymphocyte infiltration and inflammation of the CNS white matter (103) (104) (105) . Treg cells have emerged as crucial players in the pathogenic scenarios of CNS autoimmune inflammation. Targeted depletion of T cell causes spontaneous autoimmune disease in mice, whereas augmentation of Treg-cell function can prevent the development of or alleviate variants of EAE. It is interesting that Treg cells have the Janus face and a double-edged sword (13, 52, (104) (105) (106) . It is well established that CD4+CD25+ Treg cells have the capability to prevent the development of EAE and have a major role in the natural recovery from actively-induced EAE (93, (103) (104) (105) 144 (92) .
Immunity to Salmonella is typically Th1 cell dependent. Consequently, Th1 cell-dominating responses are also elicited when using conventional Salmonella vaccine vector (93) . It is very interesting that the experimental Salmonella vaccine expressing colonization factor Ag 1 (Salmonella CFA/1 vaccine) possess anti-inflammatory properties and, when mice were given a single oral dose therapeutically, increases level of CD4+CD25+Foxp3+CD4+ Treg cells and reduces further development of EAE in SJL mice and that adoptive transfer of the vaccine-induced Treg cells protects mice against EAE with greater potency than naive or Samonella vector-induced Treg cells (93) . Furthermore, oral treatment of EAE-induced SJL mice with the intracellular component Salmonella CFA/1 vaccine (Salmonella CFA1IC) greatly reduced clinical disease of EAE together with increased IL-13 production. Importantly, these Treg cells elicited with Salmonella CFA/1IC vaccine could induce high potency by simply vaccinating against irrelevant antigens, offering a novel approach to treat autoimmune diseases independently of the autoantigen (157). Recently, a gene-therapeutic approach that increases CD4+ CD25+ Treg -cell potency by antigen-specifically redirecting them against pathologic T cell was developed (95) .
Therapeutic cells are transgenetically modified with a chimeric receptors that link antigen-MHC extracellular and transmembrane domains with the cytoplasmic signaling tail of T cell receptor ζ. It was also demonstrated that CD4+CD25+ T cells or CD4+CD25+receptor-modified T cells expressing MBP prevented and treated EAE induced with MBP.
Midkine (MK), a heparin-binding growth factor, exerts pleiotropic effects,, including cell proliferation, cell migration, angiogenesis and fibrinolysis, in a variety of tissues. MK also plays important roles in the induction of oncogenesis, inflammation, and tissue repair. Furthermore, MK expression is up-regulated in the spinal cord during the induction and progression phases of EAE (96) . Currently, Wang et al have shown that MK deficiency attenuates MOG-induced EAE because of an expansion of the Treg cell population in the peripheral lymph nodes, followed by decreases in the number of autoreacive Th1 and Th17 cells. Moreover, administration of anti-MK RNA aptamers that effectively neutralize MK induced expansion of the Treg cell population and reduced the symptoms of EAE, strongly suggesting that MK is a critical suppressor of Treg cell expansion and inhibition of MK using RNA aptamers may be a potent therapeutic strategy against autoimmune diseases, including MS (96) . Recently, the U.S. Food Drug Administration approved anti-vascular endothelial growth factor aptamer as the treatment of age-related macular degeneration (145) . The experimental results reported by Wang et al also provide strong evidence for the clinical efficacy of RNA aptamers (96) . In addition, treatment of mice with VIP significantly reduced incidence and severity of EAE in a MS-related rodent model system and VIP suppressed EAE neuropathology by reducing CNS inflammation. Moreover, VIP treatment was therapeutically effective in established EAE, suggesting VIP also represents a novel multistep therapeutic approach for the future treatment of human MS.
In several current human studies, Venken et al demonstrated that patients with relapsing-remitting multiple sclerosis (RR-MS) show a suboptimal CD4+CD25+ Treg cell function, whereas no Treg cell alterations are observed in secondary progressive MS(SP-MS) patients. They analyzed the functional capacity and homeostatic parameters of naïve CD4+CD25+ CD127 low CD45RA+ Treg (nTreg) cell and their memory counterparts CD4+CD25+CD127 low CD45RO+ Treg (mTreg) cells in untreated MS patients and healthy controls with the purpose to clarify the difference in Treg cell activity between early and chronic disease stage (146) . They found that chronic MS patients had increased numbers of mTreg cells as compared with age-matches early MS patients, whereas nTreg cell frequencies did not differ significantly. TCR excision circle numbers were reduced in nTreg cells of early MS patients, suggestive of a diminished nTreg cell thymic output. Additionally, they reported that early MS patients showed a more restricted nTreg and mTreg cell gene profile. Finally, they provide strong evidence for disturbed nTreg cell development and function in MS patients (146) . Venken et al also showed that Treg cells are functionally impaired in patients with RR-MS and that aberrant FOXP3 expression at the single-cell level correlated with Treg cell dysfunction in RR-MS patients (102) . The intracellular expression of the programmed death receptor 1 (PD1) identifies a subset of naïve Treg cell with enhanced suppressive ability, and antigen stimulation results in the surface expression of PD1. Saresella et al examined naïve PD1-and PD1+ Treg cells in peripheral blood and cere-brospinal fluid (CSF) of RR-MS patients and of healthy control subjects (103) . They showed several important findings that CSF PD1-Treg cells were significantly augmented in MS patients and PD1-Treg cell were significantly increased in the peripheral blood of patients with stable disease compared to those with acute MS, and in patients responding to glatiramer acetate compared to acute-and drug-unresponsive patients. In addition, PD1+ Treg cells were similar in CSF and peripheral blood of all groups examined. The data suggest that PD1-Treg cell play a pivotal role in MS and offer a biological expansion for disease relapse (103).
Parkinson's disease, second in incidence to Alzheimer's disease is a progressive neurodegenerative disorder characterized by progress loss of substantia nigra pars compacta (SNpc) dopaminergic neurons and their projections to the caudate-putamen (147) . Surprisingly, Reynolds et al have shown that CD4+CD25+ Treg cells have neuroprotective activities in an animal model of Parkinson's disease. These results support the use of therapeutic strategies, which induce Treg cell response to attenuate neurodegeneration and inhibit dopamineric neurodegeneration associated with Parkinson's disease (147) .
Systemic lupus erythematosus (SLE)
SLE is a systemic autoimmune disease characterized by a wide spectrum of clinical manifestations, the loss of tolerance to self-antigens and the production of autoantibody (109, 113, 114) . Some studies have shown that in SLE the number of circulating Treg cells may be decreased during active disease, and that the extent of such decrease may correlate with severity of the disease (113, 179) . Recent data in murine models of lupus have suggested the possibility to target Treg cells for the modulation of SLE, and Treg-based intervention has been proposed as a novel therapeutic mean for a better management of the disease (113) (114) (115) . Injecting lupus prone (SWRxZNB)F1 mice with 1μg nucleosomal histone peptide autoepitopes subcutaneously induced potent CD4+CD25+ and CD8+ Treg cells that were effective in suppressing lupus autoimmunity without causing allergic/anaphylactic reactions or generalized immunosuppression and repaired regulatory defect in SLE upon adoptive transfer in vivo (112) . These Treg cells are not only efficient in suppressing autoantigen recognition and autoantibody production, but they also inhibit migration/accumulation of pathogenic autoimmune cells in the target organ such as the kidney of mice prone to develop lupus nephritis (109, 110) .
In several human studies, it has been suggested that Treg cells are decreased in patients with SLE (107,108,111,115) . Valencia et al demonstrated that a significant decrease in the suppressive function of CD4+CD25 high Treg cells from peripheral blood of patients with active SLE as compared with normal donors and patients with inactive SLE. Notably, Treg cells isolated from patients with active SLE expressed reduced levels of Foxp3 mRNA and protein and poorly suppressed the proliferation and cytokine secretion of CD4+ effector T cells in vitro (115) . This report may provide evidence that a reversible defect in Treg cell function in patients with active SLE and suggest that strategies to enhance the function of these cells might benefit patients with this autoimmune disease. Interestingly, glucocorticoid treatment enriched CD4+CD25
high Treg cells in patients with SLE (107,111) and upregulated expression of FOXP3 in patients with asthma (148).
Inflammatory bowel disease (IBD)
The IBD, which include Crohn's disease and ulcerative colitis, are chronic inflammatory disorders affecting ∼0.3% of the Western population. Many different pathways contribute to the maintenance of tolerance to harmless antigens in intestine. When these important pathways are compromised, chronic intestinal inflammation can develop. Particularly, Treg cells have been shown to play an important role in the prevention and cure of colitis in animal models of intestinal inflammation (118). Mottet et al provided the first evidence that established colitis could be cured by treatment with CD4+CD25+ Treg cells, resulting in resolution of the lamina propria infiltrate in the intestine and reappearance of normal intestinal architecture. Treg T cells were found to be proliferated in the mesenteric lymph nodes and inflamed area (119) . Additionally, recent data showed that Treg cells can prevent colitis by inhibiting the accumulation of tissue-seeking effector cells and that Treg cell accumulation in the intestine is dispensable for colitis suppression (120) . In patients with active Crohn's disease FOXP3+CD4+ Treg cells are expanded in mucosal lymphoid tissues (lamina propria and mesenteric lymph nodes) but are decreased in the peripheral blood and they accumulates in areas of active inflammation, including granulomas and retain potent regulatory activity ex vivo (117) . Interestingly, parenteral injection of filamenous hemagglutinin of Bordetella pertussis into SCID mice suppressed Th1 cells and pro-inflammatory cytokines and ameliorate disease activity in a chronic T cell-dependent model of colitis, suggesting filamentous hemagglutinin is a promising candidate for clinical testing in patients with Crohn's disease (116) .
Autoimmune gastritis (AIG) and acquired aplastic anemia AIG is one of the few spontaneous animal models of organ-specific autoimmune disease in which the target antigen, the proton pump of the gastric parietal cell, the H Evidence has accumulated in the recent years further corroborating an immune-mediated process underling aplastic anemia pathogenesis. In aplastic anemia, recent data demonstrated that Treg cells are significantly reduced in patients' peripheral blood and in an aplasitc murine models, infusion of Treg cells ameliorates disease progression (133) . One human study has shown that Treg cells are decreased at presentation in almost all patients with aplastic anemia. Notably, FOXP3 protein and mRNA levels also are significantly lower in patients with aplastic anemia and NFAT1 protein levels are lower in patients with anemia or absent.
Experimental autoimmune myasthenia gravis (EAMG)
Myasthenia gravis (MG) is a disorder characterized by weakness and fatigability in which autoantibodies are generated against the acethylcholine receptor (AChR) at the neuromuscular junction, thereby impairing the transmission of signals from nerve to muscle. EAMG, induced in rats by immunization with AChR, the major autoantigen in myasthenia, is a reliable model for the human disease and is suitable for investigating the mechanism(s) underlying the pathophysiology of myasthenia and for the development of novel therapeutic strategies (125) . Aricha et al has beautifully shown that Treg cells were generated ex vivo from CD4+ cells by stimulation with anti-CD3 and anti-CD28 antibodies in the presence of TGF-beta and IL-2 and administration of ex vivo-generated Treg cells to myasthenia rats inhibited the progression of EAMG and led to down-regulation of humoral AChR -specific response in Lewis rats (125) . Moreover, EAMG were suppressed by Foxp3+ Treg cells induced by injection of fms-like tyrosine kinase receptor 3-ligand (Flt3-L) or granulocyte-macrophage colony-stimulating factor (GM-CSF), potent DC growth factors before immunization of AChR (125, 127) . Furthermore, GM-CSF effectively ameliorates clinical disease severity in mice with active, ongoing EAMG. These results suggest that the selective activation of particular DC subsets in vivo using pharmacological agents, like GM-CSF, can suppress ongoing anti-AChR immune responses by mobilizing antigen-specific Treg cells capable of suppressing autoimmune MG (128) .
Experimental autoimmune thyroiditis (EAT)
EAT is a well-established mouse model for Hashimoto's thyroiditis (HT). HT is an organ-specific autoimmune disease characterized by lymphocyte infiltration of the thyroid that eventually leads to follicular destruction (129) . Administration of GM-CSF or Flt3-L resulted in suppression or augmentation of EAT, respectively. In addition, GM-CSF could induce DCs with a semimature phenotype and IL-10-producing CD4+ CD25+ Treg cells prevented GM-CSF-induced suppression of EAT. These data show the therapeutic potential of GM-CSF in EAT and other autoimmune disease with pathogenesis similar to EAT and EAMG.
Interestingly, IL-10-induced immunosuppression was due to its direct effects on mouse thyroglobulin-specific effector T cells, indicating that IL-10, produced by Treg cells that were probably induced by semimature DCS, is essential for disease suppression in GM-CSF-treated mice (129) . Moreover, the tolerogenic potential of thyroglobulin-pulsed, semimature DCs could activate thyroglobulin-specific Treg cells and suppressed the development of EAT (130) . It is of great interest that Treg cells may play a role in the natural progression of hyperthyroid Graves' disease to HT and hypothyrodisms in humans (131) .
PHARMACEUTICAL AND BIOLOGICAL PRODUCTS MODULATING Treg CELLS Superantigens (SAgs)
SAgs are the most powerful T cell mitogen ever discovered and are produced by bacteria or virus and can activated large numbers of CD4+ T cells. T-cell activation of this magnitude results in prodigious production of cytokines, which may be partly responsible for the acute toxic effects of SAgs (149) . Staphylococcus aureus enterotoxins (A, B, C, D, E, and toxic shock syndrome toxin) are the prototypic SAgs (149) (150) (151) (152) . Recently, increasing evidence suggest that SAgs play a important role in immune-mediated disease and SAgs abrogate nTreg cell activity. SAgs administration is able to significantly enhance ineffective anti-tumor immune response, resulting in potent and long-lived protective and anti-tumor immunity (149, 151) . Thus, understanding the events that control suppressive function of Treg cells may allow manipulation of these cells to inhibit or enhance their function in the development of novel therapies for autoimmune and allergic diseases, anti-tumor immunity, transplant rejection and other immune-mediated diseases (151) . These results indicate that combining the transfer of Treg cells along with that of immunomodulated DC could well substantially improve the potential of Treg cell therapy (152) .
Rapamycin Rapamycin (sirllimus), a macrolide antibiotics produced by Streptomyces hygroscopicus, is a new effective drug used to prevent allograft rejection. Similarly to the immunosuppressants FK506 and cyclosporine A, rapamycin exerts its effect by binding to the intracellular immunophilin FK506-binding protein (FKBP12). However, unlike FK506 and cyclosporine A, rapamycin does not inhibit TCR-induced calcineurin activity. Rather, the rapamycin-FKBP12 complex inhibits the serine/threonine protein kinase called mammalian target of rapamycin (mTOR), the activation of which is required for protein synthesis and cell-cycle progression. Therefore, rapamycin blocks signaling in response to cytokines, whereas FK560 and cyclosporin A exert their inhibitory effects by blocking TCR-induced activation (153) . Accumulating data have provided evidences that rapamycin selectively expands CD4+CD25+Foxp+ Treg cells and expanded Treg cells suppress proliferation of syngeneic T cells in vitro and in vivo and prevent allograft rejection in vivo. Interestingly, rapamycin does not block activation-induced cell death and proliferation of CD4+ T cells in vitro, suggesting rampamycin can be used to expand Treg cells for ex vivo cellular therapy in T-cell mediated diseases (154) . Moreover, the capacity of rapamycin to allow growth of functional CD4+CD25+FOXP3+ Treg cells in healthy and type 1 diabetic patients, but also to deplete T effector cells, can be exploited for the design of novel and safe in vitro protocols for cellular immunotherapy in T cell-mediated diseases (155) .
Vasoactive intestinal peptide (VIP) As described above in RA and CIA, administration of VIP to mice resulted in expansion and generation of CD4+CD25+ Foxp3+ Treg cells in the periphery and joints and the VIP-generated Treg cell transfer suppressed and significantly ameliorated the progression of chronic autoimmune diseases (135) (136) (137) (138) (139) . Accordingly, VIP can be used for the Treg cell therapy for immune-mediated diseases.
Midkine (MK)
As MK, a heparin-binding growth factor is a critical suppressor of Treg cell expansion and inhibition of MK using RNA aptamers may be a potent therapeutic strategy against autoimmune disease (96) .
Statins
The statins, a group of inhibitors of the 3-hydrooxy-3-methylglutaryl coenzyme A reductase, are reported to influence a variety of immune system activities. Actually, the statins are used extensively in medical practice because of their ability to reduce cardiovascular mortality and stroke (156) . Although this protective activity was initially ascribed to inhibition of cholesterol biosynthesis, it is now evident that statins are pleiotropic drugs with immunomodulatory and anti-inflammatory properties. In particular, statins treatment increased the percentage of Treg cells at inflammatory sites and in regional tissue-draining lymph nodes (156) .
Therefore, this drug may be useful for Treg cell therapy.
CONCLUSION
It is now clear that Treg cells play a central role in maintaining peripheral tolerance to self-antigen and in regulating the immune response to non-self antigens. It almost goes without saying that although defining the Treg-cell mode of action is of great academic importance, it is also essential to develop effective approaches for the clinical manipulation of Treg cells. In addition, it seems probable that a clear understanding of how Treg cell work will present definitive opportunities for successful therapeutic intervention. Although FOXP3 appears to be required for human Treg cell development and functions, expression of FOXP3 alone is clearly not sufficient for regulatory function, as a significant percentage of human activated T cells express FOXP3 but not possess regulatory activity. Therefore, further studies are required and future studies should aim (1) at identifying new markers and new relevant genes linked to FOXP3, (2) studying the effect of current and new drugs used for the treatment of autoimmune disease, allergy, tumor and transplant rejection. The cautious and scientific manipulation of Treg cells for therapeutic purposes promises to be a burgeoning field of investigation, with the potential for a wide spectrum of clinical application. A new potent Treg cell therapy will be available for the treatment of autoimmune diseases, and it might be even be an adjunct therapy for various diseases with some specific drugs. This exciting area may be an area of personalized medicine that is not being adequately addressed by the pharmaceutical industry. The discovery of more specific surface biomarkers for Treg cells is imperative, as this will undeniably facilitate our ability to monitor Treg cellular frequency and function in the context of a given disease and will serve to determine the clinical effectiveness of novel therapeutic strategies destined to modulate Treg function in vitro (Table I) . I believe that these regulatory cells may represent a kind of master switch, and by understanding how they are made, how they function and how they survive, we may be able to stop disease from occurring. 
